Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada
نویسندگان
چکیده
منابع مشابه
Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom
BACKGROUND Overactive bladder (OAB) is highly prevalent and is associated with considerable morbidity and reduced health-related quality of life. β3-adrenergic receptor (β3-AR) stimulation is a novel alternative to antimuscarinic therapy for OAB. OBJECTIVE The objective of this analysis was to assess the cost effectiveness of the β3-AR agonist mirabegron relative to tolterodine extended relea...
متن کاملEfficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER
AIMS To assess fesoterodine 8 mg efficacy over time and vs. placebo in subjects with overactive bladder (OAB) who responded suboptimally to tolterodine extended release (ER) 4 mg. METHODS In a 12-week, double-blind trial, subjects with self-reported OAB symptoms for ≥ 6 months, mean of ≥ 8 micturitions and ≥ 2 to < 15 urgency urinary incontinence (UUI) episodes/24 h, and suboptimal response t...
متن کاملSimplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder.
OBJECTIVES To compare the efficacy of tolterodine plus simplified bladder training (BT) with tolterodine alone in patients with an overactive bladder. PATIENTS AND METHODS In a multicentre, single-blind study at 51 Scandinavian centres, 505 patients aged >or= 18 years with symptoms of urinary frequency (>or= 8 micturitions/24 h) and urgency, with or without urge incontinence, were randomized ...
متن کامل[mirabegron--a New Drug for Treatment of Overactive Bladder].
Mirabegron is the first drug in a new class of oral therapy for overactive bladder (OAB). It is a beta-3 adrenergic agonist, a class of drugs for the first time used for the treatment of urination disorders. Recently, following many years of rigorous multicenter randomized trials mirabegron has been approved for use in Europe and North America. The clinical indication for mirabegron is overacti...
متن کاملCost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model.
Economic analyses of interventions for chronic diseases require evaluations over a long timeframe to illustrate the benefits and costs of treatments. Clinical trials are generally short and carried out in strictly controlled conditions. They are therefore of limited value for economic evaluation aimed at facilitating decisions about resource allocation. The objective of this study was to develo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian Urological Association Journal
سال: 2017
ISSN: 1920-1214,1911-6470
DOI: 10.5489/cuaj.4114